Does Rallies show Form 4 insider transactions for AVBP?

Yes. Rallies tracks AVBP insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is AVBP research on Rallies investment advice?

No. Rallies provides research, data, and educational context for AVBP. It does not provide personalized investment advice.

AVBP (ArriVent BioPharma, Inc. Common Stock) Stock Analysis - Insider Trades

ArriVent BioPharma, Inc. Common Stock (AVBP) is a publicly traded Healthcare sector company. As of May 20, 2026, AVBP trades at $27.24 with a market cap of $1.26B and a P/E ratio of -6.20. AVBP moved +4.09% today. Year to date, AVBP is +39.38%; over the trailing twelve months it is +30.49%. Its 52-week range spans $15.47 to $36.37. Analyst consensus is strong buy with an average price target of $44.33. Rallies surfaces AVBP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading AVBP stock inside the company?

Recent AVBP insider activity includes HILLHOUSE INVESTMENT MANAGEMENT, LTD. sold 555.55K, HILLHOUSE INVESTMENT MANAGEMENT, LTD. bought 555.55K, ORBIMED ADVISORS LLC bought 222.22K, ORBIMED ADVISORS LLC bought 222.22K, and GORDON CARL L bought 222.22K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

AVBP Key Metrics

Key financial metrics for AVBP
Metric	Value
Price	$27.24
Market Cap	$1.26B
P/E Ratio	-6.20
EPS	$-4.32
Dividend Yield	0.00%
52-Week High	$36.37
52-Week Low	$15.47
Volume	400.19K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-166.31M
Gross Margin	0.00%

Recent AVBP Insider Trades

HILLHOUSE INVESTMENT MANAGEMENT, LTD. sold 555.55K (~$12.98M) on Dec 10, 2025.
HILLHOUSE INVESTMENT MANAGEMENT, LTD. bought 555.55K (~$10.00M) on Jan 30, 2024.
ORBIMED ADVISORS LLC bought 222.22K (~$4.00M) on Jan 30, 2024.
ORBIMED ADVISORS LLC bought 222.22K (~$4.00M) on Jan 30, 2024.
GORDON CARL L bought 222.22K (~$4.00M) on Jan 30, 2024.

Latest AVBP News

ArriVent Banks $326.4M Cash, ARR-002 IND Cleared, Firmonertinib Data Due Mid-2026 — May 11, 2026
ArriVent Secures FDA Clearance for ARR-002 IND, Phase 1 Trial Slated H2 2026 — May 7, 2026
ArriVent to Present Firmonertinib Phase 3 Supporting Data and ARR-002 ADC Efficacy — Mar 17, 2026
ArriVent Secures $312.8M Cash Runway Through 3Q 2027, Phase 3 Data Due Mid-2026 — Mar 5, 2026

AVBP Analyst Consensus

9 analysts cover AVBP: 0 strong buy, 9 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $44.33.

Common questions about AVBP

Who is trading AVBP stock inside the company?: Recent AVBP insider activity includes HILLHOUSE INVESTMENT MANAGEMENT, LTD. sold 555.55K, HILLHOUSE INVESTMENT MANAGEMENT, LTD. bought 555.55K, ORBIMED ADVISORS LLC bought 222.22K, ORBIMED ADVISORS LLC bought 222.22K, and GORDON CARL L bought 222.22K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for AVBP?: Yes. Rallies tracks AVBP insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is AVBP research on Rallies investment advice?: No. Rallies provides research, data, and educational context for AVBP. It does not provide personalized investment advice.